Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenue of $6.75 million, a 17% increase year-over-year driven by recurring revenue growth from B2B2C channels [10] - Non-GAAP gross margins improved to 70.5%, up from 62.4% in Q1 2024, while core B2B2C business maintained gross margins above 81% for four consecutive quarters [12][35] - Non-GAAP operating loss decreased from $9.1 million to $5.8 million year-over-year, representing a 36% reduction [13] Business Line Data and Key Metrics Changes - The company signed 14 new clients in Q1 2025, including one national health plan, one regional health plan, and 12 employers, increasing the total client base to 97 from 83 at the end of 2024 [12][19] - Over 80% of new contracts are multi-condition, with an average contract length of three years and a renewal rate above 90% [12][19] Market Data and Key Metrics Changes - The market is shifting towards whole person digital health and platform consolidation, with employers and health plans seeking trusted partners for multi-condition care [8][20] - The company is actively engaged with multiple national and regional payers, with discussions ongoing for high-value long-term contracts [25] Company Strategy and Development Direction - The company is focused on executing a strategy centered on platform differentiation, client quality, and commercial scalability [11] - The integration of Twilio has strengthened the company's position, allowing it to support five chronic conditions under a unified brand [7][8] - The company aims to achieve operational cash flow breakeven by the end of 2025, supported by existing account extensions and new contracts [17][36] Management's Comments on Operating Environment and Future Outlook - Management noted a broader reset in the digital health market, emphasizing the importance of sustainable outcomes-driven business models [36] - The company is confident in its ability to drive sustained commercial growth and deliver measurable impact, with a robust pipeline of employer expansions and health plan launches expected in 2026 [32][34] Other Important Information - The company completed an equity raise and refinanced its debt, deferring debt amortization to 2028, which provides financial flexibility [17] - The leadership team has been strengthened with new appointments, enhancing execution and cross-functional alignment [16] Q&A Session Summary Question: Can you explain the timeline delays related to tariffs? - Management explained that delays were due to a large account transforming its offering and some specific partnerships affected by tariff issues, which impacted revenue expectations [42][43] Question: How is the partnership with RULA Health rolling out? - The company has begun systematic integration with existing clients, with positive adoption and plans for broader campaigns [48][49] Question: What is the path to cash flow breakeven by year-end? - Management indicated that achieving breakeven will be a combination of revenue growth and further reductions in operating expenses [51][53] Question: Can you provide an update on large pharma activities? - Management confirmed ongoing discussions with large pharma companies, with new contracts expected to contribute revenue in Q2 or Q3 [59][61] Question: How is the company managing contract transitions? - Management clarified that most contracts are being renewed, and transitions to different revenue models are not resulting in client losses [66][68]